» Articles » PMID: 22102277

Engagement of αIIbβ3 (GPIIb/IIIa) with ανβ3 Integrin Mediates Interaction of Melanoma Cells with Platelets: a Connection to Hematogenous Metastasis

Abstract

A mutual relationship exists between metastasizing tumor cells and components of the coagulation cascade. The exact mechanisms as to how platelets influence blood-borne metastasis, however, remain poorly understood. Here, we used murine B16 melanoma cells to observe functional aspects of how platelets contribute to the process of hematogenous metastasis. We found that platelets interfere with a distinct step of the metastasis cascade, as they promote adhesion of melanoma cells to the endothelium in vitro under shear conditions. Constitutively active platelet receptor GPIIb/IIIa (integrin αIIbβ3) expressed on Chinese hamster ovary cells promoted melanoma cell adhesion in the presence of fibrinogen, whereas blocking antibodies to aνβ3 integrin on melanoma cells or to GPIIb/IIIa significantly reduced melanoma cell adhesion to platelets. Furthermore, using intravital microscopy, we observed functional platelet-melanoma cell interactions, as platelet depletion resulted in significantly reduced melanoma cell adhesion to the injured vascular wall in vivo. Using a mouse model of hematogenous metastasis to the lung, we observed decreased metastasis of B16 melanoma cells to the lung by treatment with a mAb blocking the aν subunit of aνβ3 integrin. This effect was significantly reduced when platelets were depleted in vivo. Thus, the engagement of GPIIb/IIIa with aνβ3 integrin interaction mediates tumor cell-platelet interactions and highlights how this interaction is involved in hematogenous tumor metastasis.

Citing Articles

The role of platelets in cancer: from their influence on tumor progression to their potential use in liquid biopsy.

Morales-Pacheco M, Valenzuela-Mayen M, Gonzalez-Alatriste A, Mendoza-Almanza G, Cortes-Ramirez S, Losada-Garcia A Biomark Res. 2025; 13(1):27.

PMID: 39934930 PMC: 11818056. DOI: 10.1186/s40364-025-00742-w.


Circulating tumour cell clusters: isolation, biological significance and therapeutic implications.

Yang Y, Huang G, Lian J, Long C, Zhao B, Liu X BMJ Oncol. 2025; 3(1):e000437.

PMID: 39886139 PMC: 11557725. DOI: 10.1136/bmjonc-2024-000437.


Von Willebrand factor and hematogenous cancer metastasis under flow.

Xu W, Tan X, Li M, Xu H, Villegas J, Fu H Front Cell Dev Biol. 2024; 12:1435718.

PMID: 39282473 PMC: 11401050. DOI: 10.3389/fcell.2024.1435718.


The dynamic role of platelets in cancer progression and their therapeutic implications.

Li S, Lu Z, Wu S, Chu T, Li B, Qi F Nat Rev Cancer. 2023; 24(1):72-87.

PMID: 38040850 DOI: 10.1038/s41568-023-00639-6.


Mechanobiology and survival strategies of circulating tumor cells: a process towards the invasive and metastatic phenotype.

Kurma K, Alix-Panabieres C Front Cell Dev Biol. 2023; 11:1188499.

PMID: 37215087 PMC: 10196185. DOI: 10.3389/fcell.2023.1188499.


References
1.
Sachs U, Andrei-Selmer C, Maniar A, Weiss T, Paddock C, Orlova V . The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31). J Biol Chem. 2007; 282(32):23603-12. DOI: 10.1074/jbc.M701120200. View

2.
Amirkhosravi A, Mousa S, Amaya M, Blaydes S, Desai H, Meyer T . Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003; 90(3):549-54. DOI: 10.1160/TH03-02-0102. View

3.
Hickey M, Hutchison J, Michaud J, Sutcliffe I, Kubes P . A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ Res. 2000; 87(12):1141-8. DOI: 10.1161/01.res.87.12.1141. View

4.
Li X, Regezi J, Ross F, Blystone S, Ilic D, Leong S . Integrin alphavbeta3 mediates K1735 murine melanoma cell motility in vivo and in vitro. J Cell Sci. 2001; 114(Pt 14):2665-72. DOI: 10.1242/jcs.114.14.2665. View

5.
Langer H, Chavakis T . Leukocyte-endothelial interactions in inflammation. J Cell Mol Med. 2009; 13(7):1211-20. PMC: 2861890. DOI: 10.1111/j.1582-4934.2009.00811.x. View